Short answer
SDHA is one of the SDHx genes linked to hereditary paraganglioma-pheochromocytoma syndromes and selected SDH-deficient tumors such as some gastrointestinal stromal tumors. It matters most when the tumor pattern, pathology, or family history points toward an inherited SDH problem. The key nuance is that SDHA is often lower penetrance than the higher-risk SDHx genes, so incidental findings need more careful framing than a reflexive cancer-risk label.
How to frame the result
| Situation | Common next question | Why it matters |
|---|---|---|
| Pathogenic SDHA variant in blood or saliva | Does this change surveillance or relatives' testing? | A confirmed germline result can affect both the patient and first-degree relatives. |
| SDHA finding on tumor-only testing | Was germline testing done too? | Tumor-only results do not answer inheritance by themselves. |
| Incidental SDHA variant on a broad panel | Is this actually actionable? | Low penetrance means the clinical meaning depends heavily on personal and family history. |
| SDH-deficient GIST or PPGL pathology | Does the pathology support inherited SDH testing? | Tumor phenotype can be the clue that makes SDHA worth looking for. |
| Variant of uncertain significance | Should relatives be tested now? | VUS results usually should not drive cascade testing or surveillance changes. |
When SDHA matters most
GeneReviews recommends molecular testing for people with paraganglioma or pheochromocytoma, and it also notes that first-degree relatives of a person with a known pathogenic SDHA variant should be offered testing. At the same time, it cautions that surveillance is not recommended for incidental SDHA pathogenic variants without personal or family history because the penetrance is low. That is the practical SDHA story: useful in the right phenotype, easy to overcall if you strip away the context.
In day-to-day interpretation, the strongest SDHA clues are a PPGL or SDH-deficient tumor pattern, a relevant family history, or pathology that already points toward an SDH pathway problem. If the result came from a broad hereditary cancer panel and there is no matching clinical story, the next best step is usually a genetics review rather than assuming a generic high-risk result.
When follow-up matters more
Follow-up matters more when the finding is incidental, when the family history is weak, or when the tumor pattern does not fit SDH biology cleanly. In those cases, genetics counseling, confirmation of sample type, and a surveillance discussion tailored to the exact variant usually matter more than a reflexive broad cancer-risk label.
Questions to ask
- Was SDHA found on germline testing, tumor-only testing, or paired tumor-normal testing?
- Does the report mention SDH-deficient staining, GIST, paraganglioma, or pheochromocytoma?
- Is this an incidental result, or was there already a clinical reason to suspect an SDHx syndrome?
- What is the lab or genetics team using as the surveillance plan for this exact variant?
- Should first-degree relatives get targeted testing, and if so, on what basis?
What the result still cannot prove
An SDHA result can support hereditary risk counseling, but it does not by itself prove who will develop disease, how severe the course will be, or whether an incidental finding should change surveillance without the rest of the clinical picture.
FAQ
What does an SDHA pathogenic variant mean?
An SDHA pathogenic variant can be associated with hereditary paraganglioma-pheochromocytoma syndrome and some SDH-deficient tumors, but the result has to be interpreted with the tumor type, family history, and whether the finding came from germline or tumor testing.
Is every SDHA finding equally actionable?
No. A confirmed germline pathogenic variant with a relevant personal or family history is more actionable than an incidental SDHA finding on a broad panel. GeneReviews notes that surveillance is not recommended for incidental SDHA pathogenic variants without personal or family history because penetrance is low.
Why do people call SDHA low penetrance?
Different cohorts have estimated different risks, and SDHA generally appears less penetrant than several other SDHx genes. That is why SDHA needs careful counseling instead of a one-size-fits-all surveillance plan.
Should relatives be tested if SDHA is found?
If a pathogenic germline SDHA variant is confirmed in the family, first-degree relatives are usually offered targeted testing. If the result is tumor-only or a VUS, the family plan may be very different.
What tumors are linked with SDHA?
SDHA can be seen in paraganglioma, pheochromocytoma, and selected SDH-deficient gastrointestinal stromal tumors, and in some settings the pathology pattern can help guide whether germline testing is still needed.
What follow-up is common after SDHA testing?
Follow-up often includes genetics review, confirmation of sample type, family-history review, and a surveillance discussion that is tailored to the exact variant, the tumor pattern, and whether the finding was incidental or part of a known syndrome.